CORONA, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it's subsidiary, Watson Pharma, Inc., received a subpoena duces tecum from the Office of the Inspector General (OIG) of the Department of Health and Human Services. The subpoena requests documents related specifically to physician meetings sponsored by Watson Pharma during 2002 and 2003 with respect to Ferrlecit(R) (sodium ferric gluconate complex in sucrose injection).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Watson has adopted and implemented promotional and marketing policies that it believes are consistent with the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and intends to cooperate with the OIG to provide the requested documents.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/ .
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts about Watson are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. These forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of the investigation related to the subpoena discussed in this release; and other risks and uncertainties detailed in Watson's most recent filings with the Securities and Exchange Commission, including Watson's Annual Report on Form 10-K for the year ended December 31, 2002 and its Quarterly Report on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2003.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.CONTACT: investors, Patty Eisenhaur, +1-909-493-5611, or media, ChrisEso, +1-909-493-4013, both of Watson Pharmaceuticals, Inc.
Web site: http://www.watsonpharm.com/
